|
|
|
Substance Name: Abemaciclib mesylate
RN: 1231930-82-7
UNII: KKT462Q807
InChIKey: NCJPFQPEVDHJAZ-UHFFFAOYSA-N
Note
- A cell cycle inhibitor
NCI: An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. (NCI Thesaurus)
Molecular Formula
- C27-H32-F2-N8.C-H4-O3-S
Molecular Weight
- 602.7074
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Abemaciclib mesylate
Synonyms
- 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)-, methanesulfonate (1:1)
- Abemaciclib mesylate
- LY-2835219 methanesulfonate
- UNII-KKT462Q807
Registry Numbers
CAS Registry Number
- 1231930-82-7
FDA UNII
- KKT462Q807
System Generated Number
- 1231930827